Related Experiment Video

Updated: Jun 3, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts

Pooja Hingorani1, Wendong Zhang, Juan Lin

  • 1Department of Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona 85016, USA. phingorani@phoenixchildrens.com

Cancer
|April 8, 2011
PubMed
Abstract

Insights

Reolysin, an oncolytic reovirus, shows promise in treating pediatric sarcomas. It effectively inhibits tumor growth alone or combined with chemotherapy and radiation, offering new hope for patients with relapsed disease.

Area of Science:

  • Oncology
  • Virology
  • Pediatric Cancer Research

Background:

  • Relapsed pediatric sarcomas have poor survival rates, necessitating novel therapeutic strategies.
  • Oncolytic viruses, including reovirus, demonstrate potential against solid tumors like sarcomas.
  • Reolysin, an unmodified oncolytic reovirus, targets Ras-activated cancer cells with minimal human toxicity.

Purpose of the Study:

  • To evaluate Reolysin as a single agent and in combination therapy for pediatric sarcomas.
  • To assess the efficacy of Reolysin in preclinical models of pediatric sarcoma.

Main Methods:

  • In vitro studies using pediatric sarcoma cell lines.
  • In vivo studies using flank xenografts in mouse models.
  • Combination therapy assessment with cisplatin and radiation.
  • Cytopathic effects confirmed via electron microscopy and immunohistochemistry.

Main Results:

  • Reolysin inhibited sarcoma cell proliferation and viability in vitro.
  • In vivo administration of Reolysin reduced tumor xenograft growth and improved event-free survival.
  • Therapeutic enhancement observed when Reolysin was combined with radiation or cisplatin in specific sarcoma models.

Conclusions:

  • Reolysin demonstrates potential as a standalone therapy for pediatric sarcomas.
  • Combination therapy with Reolysin and cytotoxic agents may improve treatment outcomes.
  • Further investigation into Reolysin for pediatric sarcoma treatment is warranted.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...